Bob T. Li
Memorial Sloan Kettering Cancer Center · 577 works · 21,634 citations · h-index 60
Top works
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation
- KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
- Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer
- Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
- HER kinase inhibition in patients with HER2- and HER3-mutant cancers
- The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
- High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
- Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
- SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas
- Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors
- Accelerating Discovery of Functional Mutant Alleles in Cancer
- EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
- Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors
- Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR -Mutant Lung Cancers
- Diverse alterations associated with resistance to KRAS(G12C) inhibition
- First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
- Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance
- Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET–Rearranged Lung Cancers
- 654O Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study